Ask AI
ProCE Banner Series

Uncovering a Hidden Driver of Hypoparathyroidism: Improving ADH1 Detection and Cracking the Case With CaSR-Targeted Therapies

ADH1 is a rare but clinically significant disorder caused by calcium-sensing receptor (CaSR) variants and leading to calcium dysregulation, hypoparathyroidism, and risks to renal health. This program covers ADH1 pathophysiology, presentation, genetic testing, available and emerging treatment approaches, and patient experiences to increase HCPs’ confidence in diagnosing and managing ADH1 and improving long-term patient outcomes.

ENDO: This independent, supported Satellite Symposia is not part of the ENDO 2026 official educational programming as planned by the Endocrine Society Annual Meeting Steering Committee. This program is neither sponsored nor endorsed by the Endocrine Society. The information presented here has not been reviewed or approved by the Endocrine Society for accuracy or completeness, and the views expressed in this presentation are those of the presenters and do not represent the views of the Endocrine Society. This program may offer continuing medical education (CME) or MOC credit provided by the sponsoring organization.

ASBMR: "This Industry-Supported Symposium (ISS) will be held in conjunction with the ASBMR 2026 Annual Meeting and is not a part of the official program of the American Society for Bone and Mineral Research. Decera Clinical Education is responsible for the organization and scientific content for this event in accordance with the Essential Areas and Policies of the ACCME as well as with FDA guidelines."

FMX: “This event is not a part of the official program of FMX.”

  AAPA
  | AMA
  | ANCC
Who Should Attend

This activity is designed for clinicians involved in the management of patients with ADH1, including endocrinologists, nephrologists, primary care physicians, orthopedists, nurse practitioners, physician associates, and other members of the care team. 

All Events

Upcoming Events

June

14

2026

Uncovering a Hidden Driver of Hypoparathyroidism: Improving ADH1 Detection and Cracking the Case With CaSR-Targeted Therapies (ENDO)

6:30 AM - 8:00 AM Central Time (CT)

In-person

Hyatt Regency McCormick Place, 2233 S Dr Martin Luther King Jr Drive, Chicago, Illinois 60616

7:00 AM - 8:00 AM Central Time (CT)

Virtual

October

10

2026

Uncovering a Hidden Driver of Hypoparathyroidism: Improving ADH1 Detection and Cracking the Case With CaSR-Targeted Therapies (ASBMR)

12:45 PM - 2:00 PM Eastern Time (ET)

In-person

John B. Hynes Veterans Memorial Convention Center, 900 Boylston Street, Boston, Massachusetts 02115

1:00 PM - 2:00 PM Eastern Time (ET)

Virtual

October

21

2026

Uncovering a Hidden Driver of Hypoparathyroidism: Improving ADH1 Detection and Cracking the Case With CaSR-Targeted Therapies (FMX)

12:00 PM - 1:30 PM Central Time (CT)

In-person

Nashville, Tennessee

12:30 PM - 1:30 PM Central Time (CT)

Virtual

Topics

ADH1

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge, competence, and performance in evidence-based management of patients with ADH1. 

Target Audience
This activity is designed for clinicians involved in the management of patients with ADH1, including endocrinologists, nephrologists, primary care physicians, orthopedists, nurse practitioners, physician associates, and other members of the care team. 

Learning Objectives
Upon completion of this event, participants should be able to:

  • Identify ADH1 as an underrecognized cause of hypoparathyroidism by recognizing clinical features that raise suspicion for the diagnosis. 
  • Understand the activating mutations in the calcium-sensing receptor (CaSR) gene that underlie ADH1.
  • Apply genetic testing strategies for suspected ADH1, including appropriate test selection, result interpretation, and consideration of access and ethical implications, to confirm diagnosis and inform clinical management
  • Evaluate emerging clinical trial evidence for novel therapeutic approaches that target the underlying causes of ADH1, including CaSR-targeted therapies, to optimize calcium homeostasis and reduce renal complications

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC dba Decera Clinical Education and the HypoPARAthyroidism Association, Inc. Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.0 contact hours.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.0 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

IPCE Credit Designation

A logo for a credit companyAI-generated content may be incorrect.

This activity was planned by and for the healthcare team, and learners will receive 3.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with HypoPARAthyroidism Association, Inc.

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by an independent educational grant from BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

Partners

HypoPARAthyroidism Association, Inc

ProCE Banner

For customer support please click here.

Mailing Address:

 

Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191